Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
8
×
life sciences
national blog main
8
×
boston blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
biotech
gene editing
national
editas medicine
boulder/denver blog main
boulder/denver top stories
clinical trials
crispr therapeutics
deals
detroit blog main
detroit top stories
drugs
fda
gene therapy
glaxosmithkline
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
cancer
car-t
celgene
clinical study
What
crispr
8
×
bio
gene
cas
editing
medicine
new
roundup
big
cancer
ceo
editas
human
katrine
known
million
therapeutics
therapy
today
years
access
advanced
allergan
allogene
available
based
biopharma
biosciences
blessing
bosley
bosley's
bosley’s
bridge
bucks
capacity
car
cell
cells
cheaper
check
Language
unset
Current search:
crispr
×
crispr
×
" national blog main "
×
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells